Literature DB >> 17257085

A systematic review of the treatment studies in Huntington's disease since 1990.

Raphael M Bonelli1, Peter Hofmann.   

Abstract

Huntington's disease (HD) is an autosomal dominant, inherited, neuropsychiatric disease that gives rise to progressive motor, cognitive and behavioural symptoms. Current drug therapy has no effect on the progression of disability, and the need for any pharmacological treatment should be carefully considered. Hyperkinesias and psychiatric symptoms may respond well to pharmacotherapy, but neuropsychological deficits and dementia remain untreatable. Pharmacological intervention in the treatment of the movement disorder of HD is aimed at restoring the balance of neurotransmitters in the basal ganglia. A surprising amount of current drug therapy of HD in clinical practice is based on studies published before 1990. The authors conducted a systematic review of pharmacological therapy in HD using the available papers that were published between 1990 and 2006.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17257085     DOI: 10.1517/14656566.8.2.141

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  26 in total

1.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

2.  Key role of nuclear medicine in seeking biomarkers of Huntington's disease.

Authors:  Ferdinando Squitieri; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

3.  Tracking motor impairments in the progression of Huntington's disease.

Authors:  Jeffery D Long; Jane S Paulsen; Karen Marder; Ying Zhang; Ji-In Kim; James A Mills
Journal:  Mov Disord       Date:  2013-10-21       Impact factor: 10.338

4.  An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.

Authors:  Anthony L Vaccarino; Karen Anderson; Beth Borowsky; Kevin Duff; Joseph Giuliano; Mark Guttman; Aileen K Ho; Michael Orth; Jane S Paulsen; Terrence Sills; Daniel P van Kammen; Kenneth R Evans
Journal:  Mov Disord       Date:  2011-03-02       Impact factor: 10.338

Review 5.  Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.

Authors:  Laurie Galvan; Véronique M André; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  J Huntingtons Dis       Date:  2012

6.  Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.

Authors:  Anna Parievsky; Cindy Moore; Talia Kamdjou; Carlos Cepeda; Charles K Meshul; Michael S Levine
Journal:  Neurobiol Dis       Date:  2017-07-27       Impact factor: 5.996

7.  Using zebrafish to assess the impact of drugs on neural development and function.

Authors:  Su Guo
Journal:  Expert Opin Drug Discov       Date:  2009-07-01       Impact factor: 6.098

8.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Recent advances in the management of choreas.

Authors:  Jean-Marc Burgunder
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

10.  Aripiprazole in the treatment of Huntington's disease: a case series.

Authors:  Andrea Ciammola; Jenny Sassone; Clarissa Colciago; Niccolò E Mencacci; Barbara Poletti; Andrea Ciarmiello; Ferdinando Squitieri; Vincenzo Silani
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.